@FierceMedDev: Abbott Breakup Plans Are on Target as Profit Tops Estimates | Bloomberg. Article | Follow @FierceMedDev
> AdvaMed is urging Congress to ensure "swift passage" of the medical device user fee authorization renewal as negotiated. Release
> Abbott Laboratories ($ABT) says plans to split off into a two companies--one focused on new drugs, the other, on medical devices, generic medicines and nutritional drinks--are on track for completion by the end of 2012. Story
> Quest Diagnostics boosted revenue 6.3% to $1.9 billion for its fiscal 2012 first quarter, driven by a 6.4% jump in clinical testing revenue, a number that spiked a bit due to acquisitions. Release
> A Senate committee later this month will consider a newly filed bill designed to ensure pediatric studies are completed for devices and drugs; make sure studies are planned earlier in the development process; and make permanent the pediatric medical device incentive and the pediatric device consortia initiative. Release
> Italian researchers say that a new "fast and inexpensive" imaging technique known as digital chest tomosynthesis is showing promise as a way to screen for lung cancer. Release
Pharma News
@FiercePharma: Pfizer's still working with Nestle and Danone in nutrition-unit sale, Bloomberg says, though Danone thinks it won't win. Article | Follow @FiercePharma
> Another day, another deal for Valeant's Pearson. Story
> J&J plant fixes behind schedule, hampering brands' return. Report
> Humira sales leap helps power Abbott earnings. Item
> Mylan pledges 500 new jobs in Irish expansion. Article
> WSJ: Pfizer poised to sell nutrition biz to Nestlé for $9B-plus. News
Biotech News
@FierceBiotech: Fierce's Top 10 Late-Stage Cancer Drugs -- 2012. Report | Follow @FierceBiotech
@JohnCFierce: GSK doubles down on drug discovery collaboration with FivePrime, a Fierce 15 company in 2004. News | Follow @JohnCFierce
@RyanMFierce: Google VC fuels Series A round for pharma software startup Wingu, aims to capitalize on open R&D trend. Story | Follow @RyanMFierce
> Abbott touts positive Parkinson's PhIII as pharma split looms. More
> Crucell and Royal DSM pull the plug on biosimilar JV. News
> J&J and Bristol-Myers ally on another potential hep C blockbuster. Article
> Roche says it won't extend Illumina offer past Friday deadline. Item
Drug Delivery News
> Meet the new editor of FierceDrugDelivery. Item
> Novo: Delivery devices could make biosimilars unsafe. More
> Dutch firm gets Fox Foundation funding for PD tech. Story
> BDSI gets patent for anti-opioid film. News
> pSivida stock rallies after Durasert partnerships. Article
Biomarkers News
> Saliva test could aid dentists in oral cancer diagnosis. Story
> RNA markers for blast-induced traumatic brain injury. Item
> Postmenopausal osteoporosis fingerprinted by miRNAs. More
> Chemo-resistance proteins mark defiant breast tumors. Article
And Finally... Competitive bidding for power wheelchairs, diabetic supplies and other personal medical equipment helped save Medicare $200 million last year, the agency says. Story